

Index

- African Commission, Working Group of Experts on Indigenous Populations/Communities 220–21
 - African Regional Intellectual Property Organization 208
 - Agreement on Trade-Related Aspects of Intellectual Property Rights *see* TRIPS Agreement
 - Anti-Unfair Competition Law (China 1993, 2018) 310, 326–7
 - Art 1 312
 - Art 2 324, 325
 - Art 2(1), 311
 - Art 2(2), 311
 - Art 2(3), 311
 - Art 6 311
 - Art 7 311
 - Art 8 311
 - Art 9 311, 314
 - Art 10 311
 - Art 11 311
 - Art 12 312
 - Art 12(1), 323
 - Art 12(2), 323
 - Art 12(3), 323
 - Art 12(4), 317, 323
 - commercial slander 311
 - false advertisement 311
 - General Clause 310, 311–12
 - balance of interests 325–6
 - case law *see* China unfair internet competition litigation
 - Catchall Provision 313, 316
 - complementary application 313
 - flexibility of 313
 - Imperial Provision 312, 313, 316
 - protection of freedom of competition 311
 - regulation of unfair competition 316
 - sole application 313, 324
 - criticism of 313–14
 - limitations 316–17
 - Internet Clause 312, 316–17, 325–6
 - internet traffic hijacking 323
 - Junior Catchall Clause 317
 - likelihood of confusion 311
 - malicious incompatibility 323
 - restricting choice of users 323
 - unfair commercial practice 311 *see also* China; unfair competition
- Australia
 - Aboriginal and Torres Strait Islander Library, Information and Resource Network 233
 - Corporations Act (2001) sec 180(2) 162–3
 - Library and Information Association protocols for handling Indigenous heritage 232–3
 - authors' rights *see* copyright
- Berne Convention 98
 - acceptability of fair use under 13
 - Appendix 2
 - compulsory licensing scheme 99, 105–7
 - criticism of 107
 - Art 6*bis* 1
 - Art 9(2) 13
 - copyright limitations & exceptions in 101, 102

- Art 10(1)
 - copyright limitations and exceptions in 101–2, 103
 - proportionality test 102–3
- Art 14*ter* 79
- Art 17, 13
- common law judicial power
 - compatibility with 12–14
- reproduction and translation rights under 98
- three-step test 13–14, 16–19
 - certain special cases 16–17
 - as guideline 16
 - judicial interpretation 26–8
 - no unreasonable interference 18
 - normal exploitation 17–18
- US accession to 13
- bilateral investment treaties 4
- biomedical innovation 243–4
 - and AI & big data 260–62
 - ethics-based objections to behaviour of owner 250
- gene editing 257–60
 - CRISPR-Cas9 technology 258
 - germline intervention 263
 - in human embryos 258–9
 - patentability 260
 - somatic cell interventions 259
- issues in patentability 263
- jurisprudential opportunities of 249
- morality exceptions as bioethics policy tool 252
- and patent law morality exception 252–3
- stem cell therapy, 253–7
 - Brüstle* case 255–6, 257
 - complex ethical issues of 253, 254
 - defining human embryo 255
 - human embryonic stem cells 254
 - International Stem Cell Corporation* case 257
 - patentability 253–4, 256
 - WARF* case 254
- see also* morality; ordre public; patents
- business judgment rule 4, 146, 161, 170
 - defence 162–3
 - as shield from accountability 163–4
 - UK application 163–5
- Canada
 - EU Comprehensive and Economic Trade Agreement 179–80
 - Art 8.10 190
 - Patent Act 348
 - patentability requirements 189
 - promise utility doctrine 183, 184, 187
 - see also* investment arbitration
- certified global food chains 4–5, 195–7, 212–13
- brand control 196, 201–3
- certification marks 206–7
- collective marks 206
- consumer perception of new food 201–2
- FETA* case 204
- geographical indications for agricultural products 203–6
- optional quality labels 206
- Protected Designation of Origin 204–5
- Protected Geographical Indications 203–4
- protection 205
- trademarks 208–9
- Traditional Speciality Guaranteed 205
- types of chains 202–3
- consumer power in 195
- enhancing fairness in 210
 - public interest and TRIPs obligations 210–11
 - public interest and WTO/GATT obligations 211–12
- food development 195, 196–7
- food industry 195–6
- regulation
 - EU 198–200
 - vs control 197
- traditions in 196
- see also* EU food regulation; TRIPs Agreement

- China
- Anti-Unfair Competition Law *see* Anti-Unfair Competition Law (China 1993, 2018)
 - freedom of competition, boundaries 315–16
 - Interim Measures for Internet Advertising Management Art 16(1) 324
 - rapid development of internet industry 310
 - Supreme People's Court's Provisions on the Work of Guiding Case System (2010) 324
 - unfair internet competition litigation 310, 317–18
 - Baidu v. Qihoo 360* 318–19, 323, 325, 326
 - Dianping.com v. Baidu* 325
 - effects of precedent cases 324–5
 - general evaluation 323–4
 - judicial decision-making 323
 - Kelp Quota* case 314–16, 317, 324–5
 - Tencent v. Qihoo 360* 319–20, 323, 326
 - Tencent v. Star World Technology* 320–22, 323–4
 - circular economy theory 144, 169
 - common law 3, 8
 - centrality of role of judges 9
 - copyright 8–9
 - exceptions 8
 - formalism of 8
 - judicial power in 11–12
 - compatibility with Berne Convention 12–14
 - compatibility with Information Society Directive 14–16
 - open-ended 13
 - restriction of 14
 - scope 15
 - statutory limitations 8
 - see also* Berne Convention; copyright; UK
 - conveyancing
 - authors' rights model
 - implied transfers 49
 - Garcia v Google* 49–50
 - US model
 - author's signature requirement 49
 - deception/unconscionability 49–50
 - no implied transfers 49
 - work-made for hire 49
 - copying technology
 - and copyright exemptions 59–60
 - progress in 124
 - copyright 8–9, 141
 - and access to textbooks *see* rights to education
 - authors' rights model
 - co-authorship 33–4
 - collaborative works 33–4, 37–8
 - contributors as authors 33
 - inalienability of moral rights 52
 - presumptive author status 33, 34
 - work as extension of creator 51–2
 - as beyond reach of human rights law 100
 - case law
 - Aalmuhammed v Lee* 36–7
 - Childress v Taylor* 36
 - Thomson v Larson* 36
 - compulsory licensing 105–7
 - compensation 106
 - reproduction 106
 - restrictions 106–7
 - translation 106
 - creative commons
 - Indigenous Knowledge Notice 236
 - licences 236–7
 - share-alike provisions 70
 - creators' rights 31
 - economic rationale 125
 - enabling owners to appropriate value of copying 127–8
 - exemptions 53, 101
 - advantages of 54
 - beneficial to mass-copying technologies 59–60
 - in Berne Convention 101–2
 - changing nature of 56, 57

- digital private copying 65–7
- doctrinal implications 56–7
- for libraries 104–5
- not compulsory 103
- parody/pastiche 127
- problems of 54–5
- public interest 99, 101
- public security 14–15
- time-shifting 65
- expanding subject-matter 9
- fair dealing *see* fair dealing
- fair use *see* fair use
- fairness in *see* fairness
- formalism of 9
- Hargreaves Review 53
- and human rights *see* human rights
- limitations 101
 - in Berne Convention 101–2
 - for libraries 104–5
 - not compulsory 103
- mainstream economic approach to 76–7
- not creating monopoly power 127
- opt-out rules 72–3
 - and tech-enabled uses 74
- price control 128
 - and public interest 9–10
- resale rights 48
- restoration 50–51
- and right to education *see* right to education
- substantive rights *see* conveyancing; moral rights; remuneration; revocation rights
- term of protection 41, 45
- three-step test in TRIPS 103
- US model 33, 34
 - certainty in 52
 - collaborative works 34
 - commissioned works 35
 - confusion over 35
 - considered property 49
 - contract negotiation 50
 - employer as copyright owner 34, 35
 - instance and expense test 36
 - intent to share authorship 37
 - joint works 36–7
 - not about authors' rights 51
 - work-made-for-hire concept 34–6
- US/authors' rights regimes
 - differences 51–2
 - what constitutes authorship 33–4
- corporate governance
 - accountability and transparency 152
 - board oversight 146–8
 - directors 147–8
 - business judgment defence 162–3
 - In re Walt Disney Co.* 164
 - directors' accountability
 - Revlon, Inc. v MacAndrews & Forbes Holdings, Inc* 164–5
- governance deficiencies 151–3
 - data privacy 151–2
 - IP policies 151
- governance shortfalls 148–51
 - composition of board 149–50
 - fraud 148, 150
 - misconduct 151
 - oversight 148–9
- new global regulatory discourse 151
- in UK *see* UK corporate governance
 - see also* IP, and corporate governance
- digital libraries
 - challenge to online access to digital heritage 226
 - clash of knowledge systems 227
 - dominant perspective 226
 - IFLA/UNESCO digital Library Manifesto 229
 - increasingly impacting rights holder interests 226
 - Indigenous librarianship 227
 - and Indigenous peoples' IP rights 218
 - concerns of source communities 227–8
 - digitization of TCEs 227
 - indigenous data sovereignty 226–9, 238–40
 - knowledge commons 235–8
 - privacy by design 234–5

- public sphere 240–41
- respect and consultation 229
- traditional cultural expressions
 - see* traditional cultural expressions
- lacking ‘natural’ restrictions on dissemination 226
- see also* libraries
- Doha Declaration 2
- emerging technologies 249, 252, 263–4
- Enlightenment 220, 221
- EU
 - Canada Comprehensive and Economic Trade Agreement Art 8.10(2) 180
 - Charter 261
 - Art 11 29
 - CJEU 15
 - Brüstle* case 255–6, 257
 - International Stem Cell Corporation* case 257
 - Commission Recommendation of 17 July 2012 on Access to and Preservation of Scientific Information 274–5
 - Competition and Markets Authority 342
 - copyright law, and public interest 28–9
 - Court of Human Rights margin of appreciation doctrine 185
 - Directive 98/44/EC (biotechnology) 243–4, 251
 - Art 6 243
 - Art 6(2)(c) 255, 256
 - incorporation of Art 53(a) into EPC Implementing Regulations 252
 - interpretation 262
 - recital 26 261
 - recital 42 260
 - Directive 2001/29/EC (information society) 9–10, 12
 - Art 3(1), 29
 - Art 5(3)(e) 14–15
 - Art 5(3)(o) 14
 - Art 9 15
 - compatibility of common law judicial power with 14–16
 - exhaustive statutory limitations 15
 - recital 3 15
 - recital 31 14
 - recital 32 15
 - Directive 2001/84/EC (resale rights) 48, 78, 79–80
 - Directive 2004/48/EC (enforcement) Art 12 306, 308
 - Directive 2014/95/EU (non-financial disclosure) 168
 - Directive 2019/790 (DSM) 41–2
 - Art 18 41
 - Art 19 41–42
 - Art 20 42
 - Art 22 45
 - Ch 3 41, 42
 - Directive (EU) 2016/943 (trade secrets) 288
 - Art 5(d) 291–2
 - Art 6 300
 - Art 7 300
 - Art 7(2) 299
 - Art 10(2) 307
 - Art 10(3)(a) 298
 - Art 11(2) 292
 - Art 13(1) 292, 299
 - Art 13(3) 300, 306
 - Art 14(1) 305
 - unfair competition approach 290
 - Europe 2020 Strategy 274
 - European Convention on Human Rights 15
 - food regulation
 - certification marks 206–7
 - collective mark 206
 - General Food Law 199–200
 - geographical indications 203–4
 - marketing 199–200
 - Novel Food Regulation 198–9
 - novel/functional foods 198–9
 - traditional foods from outside EU 199
 - G S Media v Sanoma* 28–9

- Horizon 2020 program 275
- Intellectual Property Office 208
- and open science *see* open science
- Regulation (EU) 536/2014 (data protection) 260–61
- Trademark Regulations (2009) 344
- Treaty on the Functioning of the European Union
 - Art 101(1) 344
 - Art 102 342
- see also* certified global food chains; trade secrets
- European Patent Convention 243, 247
 - Art 53 247, 249, 253
 - Art 53(a) 266
- Implementing Regulations
 - incorporation of Art 53(a)
 - Biotechnology Directive 252
 - Reg 26(1) 251
 - Rule 28(1)(b) 259
 - Rule 28(1)(c) 255
 - Rule (28) 252
 - Rule 28(c) 254
- morality and ordre public
 - exceptions 243, 264
- no statutory definition of morality or ordre public 247
- only considering morality of
 - commercial exploitation of invention 250
- see also* morality; ordre public; patents
- European Patent Office
 - Boards of Appeal
 - Breast and ovarian cancer* 250
 - guidance 247–248
 - OncoMouse* 248
 - Plant cells* 248
 - Relaxin* 248
 - Technion* 257
 - Transgenic Animal* 248
 - CJEU judgments not binding 251–2
 - Enlarged Board of Appeal
 - Programs for computers* 249
 - Transgenic plant* 250
 - WARF* 254
 - Examination Guidelines 257
- see also* morality; ordre public; patents
- extraterritorial state obligations 96–7, 99–100, 109–13
- in ICESCR 109
- and IP law 100–101, 103, 123
- in Maastricht Principles *see* Maastricht Principles
- and right to education
 - to facilitate 110, 113, 115–17, 118–22
 - to fulfil 110, 113
 - to protect 110–11, 113, 114
 - to provide 110, 111, 117–18
 - to respect 110, 113–14
 - when arising 111
- see also* right to education
- fair and equitable treatment 193
 - as ambiguous standard 174, 186, 194
 - investment arbitration *see* investment arbitration
 - Art 1105 NAFTA standard 181
 - due process 181
 - /expropriation of investment assets distinction 174
 - FET clauses
 - interpretation 178, 179–80, 186–7
 - liability threshold 175, 177, 194
 - and MST 178, 179–80
 - referencing international law 177
 - stand-alone 177–8
 - ubiquity of 177
 - history 175–7
 - and IP 174–5
 - IP exclusion 174
 - prohibitions
 - arbitrariness 181, 186
 - denial of justice 180–81
 - discrimination 181
 - protection of investor's legitimate expectations 181–2
 - transparency 181
 - see also* Canada; international investment law; NAFTA; Uruguay

- fair use/dealing 9, 13, 137
 case law
 Associated Press v Meltwater
 68–9
 British Oxygen Co. Ltd 128–9
 Google Books cases 60–61, 67–8,
 69
 defence 60–61
 public benefit concept 60, 61–2
 determinants 127–9
 and economic growth 4, 124
 effect on economic growth 131–2
 analysis 132–3
 exceptions 53
 changing nature of 58
 digital private copying 65–7
 doctrinal implications 56–7
 mass-copying technologies 60
 no longer just safety net 53–4
 and tech companies 55, 57–8
 temporary copying 58–9
 transfer of power 58, 65
 transformative works 61, 64–5,
 68
 exclusivity 3, 53, 55, 56, 74–5
 as frustrating purpose of fair use
 67–8
 Google Books programme 60, 61,
 62–3
 non-replicable use 62–3, 72
 potential for share-alike
 provisions 70–71
 and sole-source databases 71–2
 Turnitin/iParadigms 63–5
 four pillars of
 amount and substantiality of
 portion used 129
 effect of the use on the potential
 market 129
 nature of the copyrighted work
 128–9
 objective and character of the use
 128
Google narrative 53, 60
 implications of 129–31
 benefits 131
 costs 130–31
 decreasing producer surplus 130
 increase in direct costs 129
 increased consumer surplus 130
 loss of revenues 130
 shift in supply and demand
 129–30
 intense lobbying for 57, 58
 as judicially created 56
 as legal term 125
 market factor in 68–70
 and market power 59–60
 negative impact on owner's
 incentive 127
 open-ended nature of 13
 optimal 127
 and opt-outs 72–4
 phases 127
 rise of fair use industries 57–9
 technological 64
 TRIPS model 126–7
 three-step test 126
 UK model
 closed list, 126
 US model 54, 125–6
 open list 126
 see also copyright
 fairness 1, 95
 applicability to trademarks 1
 for authors and performers 31, 33
 consequentialist conception 93
 in copyright 3
 difficulty defining 32, 77, 91
 and distributive justice 77, 78, 90
 dynamism of 9
 factoring into copyright 90–95
 gap 32–3
 human rights principles as
 normative 215
 integrating welfare and 88
 La Peau de l'Ours fund 77–8
 as early resale rights system 78
 as mattering in practice 77
 measurability 93, 94
 preferences 94
 contradicting rationality models
 89–90
 intermediaries 89
 visual artists 89
 public interest as proxy for 9

- resale rights *see* resale rights
- resale royalties *see* resale royalties
- use in IP 1
- voluntary payment of resale royalties 90
- /welfare
 - incompatibility thesis 91–2
 - integration 92–3
- /welfare maximization interaction 95
- see also* copyright; fair dealing; fair use; human rights

- General Agreement on Tariffs and Trade 211–12
- Art XX 211–12
- ordre public in 212
- US-Shrimp* case 211

- hierarchy of civilizations concept 221
- human rights 4
 - collective rights absence in 222
 - education *see* right to education
 - extraterritorial state obligations *see* extraterritorial state obligations
 - Indigenous peoples' *see* Indigenous peoples
 - principles as normative fairness 215, 217
 - right to education *see* right to education
 - self-determination *see* self-determination

- ICESCR
 - Art 2(1) 109
 - Art 13 107–8, 109
 - acceptability in 108–9
 - accessibility in 108
 - availability in 108
 - human rights in 109
 - right to education 109
 - see also* right to education
- India, Essential Commodities Act (1955) 345
- Indigenous data sovereignty 238–40, 241–2
 - and digital libraries 239
 - Indigenous Navigator 238
 - kaitiaki* 240
 - multifaceted nature of 238–9
 - operationalizing self-determination 234
 - knowledge commons 235–8
 - privacy by design 234–5
 - public sphere 240–41
 - problems of 238
 - rangatiratanga* 240
 - reestablishing Indigenous authority 239–40
 - taonga* 240
 - and UNDRIP 239
 - Waitangi Tribunal Report into Wai 262 claim 239–40
 - see also* digital libraries; traditional cultural expressions; traditional knowledge
- Indigenous peoples
 - as both term and movement 220–21
 - cultural assimilation 221
 - cultural destruction 221
 - heritage 215
 - #NoDAPL protests 215
 - and copyright 216–17
 - and digital libraries 218
 - exclusion and dispossession 215–16
 - intangible *see below*
 - and *scientia nullius* doctrine 216
 - systematic exclusion from IP protection 216
 - traditional cultural expressions *see* traditional cultural expressions
 - traditional knowledge *see* traditional knowledge
- human rights 217
 - early assimilationist character 222–3
 - enjoyment of moral and material benefits of IP 217
 - free prior and informed consent 217
 - participation 217, 222–5

- self-determination 217, 218, 219, 221
- Indigenous librarianship 227
- Indigenous/scientific knowledge
 - differences 225
- intangible heritage
 - and copyright 222
 - dominant legal framework 222, 223
- IP rights
 - difficulties participating in
 - norm-setting 222
 - difficulties with copyright 224
 - fight for collective rights 222
 - Indigenous data sovereignty *see* Indigenous data sovereignty
 - see also* digital libraries
- international investment law 173–5
 - bilateral investment treaties 176–7
 - international investment agreements 173
 - investment arbitration *see* investment arbitration
 - investment protection 173
 - FET standard 173
 - host state obligations 173
 - illegal expropriation 173
 - most-favoured-nation-treatment 173
 - national treatment 173
 - investor-state dispute settlement
 - system 173
 - minimum standard of treatment 175
 - see also* fair and equitable treatment
- International Labour Organization, Convention No. 107 on Indigenous and Tribal Populations (1957) 222–3
- investment arbitration
 - Eli Lilly v Canada* 183–4, 193
 - arbitrariness 187
 - discrimination 192–3
 - legitimate expectations 188–90
- liability threshold 194
- Philip Morris v Uruguay* 182–3, 193
 - arbitrariness 185–7
 - denial of justice 190–92
 - legitimate expectations 188
 - see also* Canada; Uruguay
- IP
 - 5IR technology 143–4
 - corporate 4, 142
 - new era of accountability 144
 - and corporate governance 144–6, 169–70
 - best practice 61–2
 - board accountability 152–3
 - Chief IP Officer 167–8
 - director IP knowledge 170–72
 - external IP and technology
 - advisors 166–7
 - Facebook Inc* case 151–2
 - minimum acceptable IP
 - knowledge 161–3, 164–5
 - technology and IP advisory boards 165–6
 - Theranos Inc* case 148–51
 - crisis of legitimacy 224
 - international rules 2–3
 - as investment asset 174
 - and ISDS 4
 - law
 - /corporate law cross-referencing 143
 - FET standard *see* fair and equitable treatment
 - protection
 - copyright *see* copyright
 - creators' exclusive rights 124
 - justification for 124–5
 - rights *see* IP rights
 - Russia 6, 353–354
 - see also* corporate governance
- IP rights
 - copyright *see* copyright
 - designs 141
 - digital libraries *see* digital libraries
 - Indigenous peoples' *see* Indigenous peoples
 - intangible and unseen 141
 - as intangible version of wealth 141
 - need for new approach to 144
 - not absolute 182
 - overcoming free rider problem 142–3

- patents 5, 141
 - public awareness of 141–2
 - societal benefits 142
 - source communities 216
 - as striking balance 143
 - trade secrets 141
 - trademarks *see* trademarks
 - ubiquity of 170
- libraries
- access to culture via 220
 - American Library Association
 - Bill of Rights 228
 - Core Values 228
 - Draft Principles Librarianship and Traditional Cultural Expressions (2009) 228–9
 - support for Indigenous self-determination, 228
 - concept of 219
 - digital *see* digital libraries
 - dominant perspectives 225
 - functions 220
 - as heritage institutions 220
 - and Indigenous peoples' heritage 220–21
 - protocols for handling 232–3
 - as reflecting society 226
 - source communities 219–20
 - see also* traditional cultural expressions
- Maastricht Principles (2011)
- extraterritorial state obligations in 96, 109–10, 111
 - Principle 14 113
 - Principle 15 111–12
 - Principle 17 112
 - Principle 29 112–13
- Marrakech Treaty 3
- medicines *see* pharmaceuticals
- moral rights 1, 42–4
- attribution 43
 - authors' rights model
 - EU 42–3
 - France 43
 - integrity 43
- Turner v Huston* 43
 - US model 31, 35
 - extremely limited 43–4
 - fully waivable 44
 - morality 1–2, 266–7
 - in bioscience *see* biomedical innovation
 - compliance 249
 - EU patent law 250–52
 - European patent law, European Patent Convention 247, 251
 - exception as technologically neutral 253
 - exceptions rarely applied 253
 - innovation and legal interpretation 263–4
 - international patent law 244, 246–7
 - Paris Agreement 246
 - TRIPS Art 27 246–7
 - limitations 249–50
 - patent law exclusions 264–5
 - as policy tool 262
 - Biotechnology Directive interpretation 262
 - germline intervention 263
 - morality-based clauses 262–3
 - no immunity to accepted bioethics principles 263
 - patentability 263
 - provisions as indirect bioethics policy tool 252
 - see also* biomedical innovation; ordre public; patents
 - North American Free Trade Agreement
 - Art 1105 177, 178, 181, 183, 190
 - Art 1110 183
 - Notes of Interpretation of Certain Chapter 11 Provisions' (2001) 179, 190
 - open science, 5, 268, 286–7
 - Argentinian policy 281
 - characteristic element of 268–9
 - collectivism principle 271
 - Colombian policy 283–4

- access to research 284
- guidelines 283
- EU policy 272–5
 - A Digital Agenda for Europe 274
 - access to scientific information 273
 - Commission Recommendation (2012) 274–5
 - European Open Science Cloud 275
 - fair competition 274
 - framework programs for research 272
 - incentives for small/independent researchers 274–5
 - management of IP in knowledge transfer 273
 - non-restrictive licensing system 274
 - Open Research Publishing Platform 275
 - publicly-funded research 274
 - transparency 274
 - Union for Innovation 274
- exclusivity 271
- Finnish policy 278–9
 - access to research 278
 - Open Science and Research Roadmap (2014–2017) 278
- German policy 276–7
 - access to research 277
 - Digital Information initiative 276
 - Open Access in Deutschland strategy 277
 - strong protection system 276
 - updated copyright law 277
- initiative findings 286
- and IP 268–9, 271
 - as complementary systems 271
 - dichotomy 269, 271
- Mexican policy 281–2
 - implementation 281–2
 - Open Science Committee 282
- no unanimous definition of 268
- OECD Guidelines 284–5
 - Principles and Guidelines for Access to Research Data from Public Funding 284
- Peruvian policy 282, 283
 - and IP 283
 - National Digital Repository for Open Access Science, Technology and Innovation 282
 - publicly-funded research 282–3
- taxonomy of 270
- transmissibility 271
- US policy 279–80
 - constitutional status of scientific progress 279
 - Education Resources Information Center 279
 - MEDLINE 279
 - opening of information 279–80
- ordre public 1
 - in bioscience *see* biomedical innovation
- compliance 249
- EU Unfair Commercial Practices Directive 1
- European patents case law 248
- no statutory definition 248
- not to be confused with public order 1
- patent exception 244, 246
- patent law exclusions 264–5
- underlying Berne Convention 13
- see also* morality; patents
- Organisation Africaine de la Propriété Intellectuelle 208
- Organisation for Economic Co-operation and Development 197
- Guidelines 284–5
 - Principles and Guidelines for Access to Research Data from Public Funding 284
- parallel imports 114, 121–2, 344
- Paris Convention (1883) 2, 246
 - Art 6*quinquies* 1
 - Art 7*bis* 210
 - Art 10*bis* 32
- patents 5, 141
 - as administrative concessions 245

- in biosciences *see* biomedical innovation
- ethics-based rules 245–6
- European Patent Convention 243
- exceptions
 - morality *see* morality
 - ordre public *see* ordre public
- independent of market regulatory approval 245
- justifications 244
- limitations
 - compulsory license mechanisms 244
 - research exemptions 244
- patent rights 245
- patentability 246
- see also* European Patent Convention; European Patents Office
- performance right 31, 40
- pharmaceutical pricing 6, 330
 - applicability of foreign laws 333–4
 - Animal Science Products v. Habei Welcome Pharmaceutical Company* 334
- Canada 348
 - Alexion Pharmaceuticals Inc v. Attorney General of Canada* 348
 - Patented Medicine Price Review Board 348
- and competition law 339–42
 - abuse of dominance 333, 340, 351
 - Competition Act 2002 (India) 340, 341
 - EU 342–4
 - Hazel Tau & others v. GlaxoSmithKline & Boehringer Ingelheim* 342
 - monopolies 339–40
 - need for intervention by
 - competition authorities 339, 340–41, 342
 - no-objection certificates (India) 340–41
 - Shamsher Kataria v. Honda Seil and others* 340
 - South Africa 342
 - unfair prices 340
- cost of development to market 331
 - disclosure of 331–2
 - determining fair price 331
- e-pharmacy 338
- EU
 - Astra Zeneca v. Commission* 343
 - Competition and Markets Authority 342
 - GlaxoSmithKline Services v. Commission* 344
 - IMS Health v. NDC Health Care* 343
 - Junek Europ-Vertrieb GmbH v Lohmann & Rauscher International GmbH & Co* 344
 - licensing 343
 - Lundbeck v. Commission General Court* 344
 - settlement agreements 344
- external/international reference pricing 349–50
- generic names and drugs 335–6
 - Activities Report of the Generic Drugs Program (FY 2018) 336
 - Drugs and Cosmetic Rules 1945/2018 (India) 335
 - International Non-proprietary Name system 335
 - misplaced concentration on 336
- health insurance schemes 337–8
 - India 337
 - US 337–8
 - US National Federation of Independent Business v. Sebelius* 337
- health technology assessments 349
- India
 - and compulsory licences 333
 - cost-plus pricing 346
 - Drug (Prices Control) Orders 332, 345
 - essential medicines 345, 346
 - exemptions 346
 - information asymmetry in 346–7

- market-based 345
- maximum retail price 346
- National Pharmaceutical Pricing Authority 332, 345
- price monitoring and research units 332–3
- reasonably affordable price 333
- standing committee on affordable medicines and health products 347–8
- Uniform Code of Pharmaceuticals Marketing Practices 347
- Wholesale Price Index 332
- no single formula to fix prices 351
- payment on value contracts 350–52
 - fee for service payments 351
 - money back guarantees 351
 - as unlawful inducement 351
- PhRMA Guiding Principles on
 - Direct-to-Consumer Advertisements About Prescription Medicines 331
- price monitoring 332–3
 - Health Action International 332
 - Médecins Sans Frontières 332
- product hopping 343–4
- rapidly increasing prices 352
- UK
 - de-branded medicines 348
 - statutory regulation 348
 - voluntary profit cap 348
- US 343
 - and Sherman Antitrust Act (1890) 334
 - State of New York v. Actavis* 343
 - The Patient Right to Know Drug Prices Act (2018) 332
- Vaccine Product Price and Procurement web platform 332
- value extraction 349–50
- WHO Global Price Reporting Mechanism 332
- pharmaceuticals 328–30
 - African Network for Drugs and Diagnostics Innovation 329
 - alternative medicine 328
 - diseases of the affluent 329
 - diseases of the poor or neglected 329
 - Drugs and Magic Remedies [objectionable advertisements] Act (1954) 328
 - Drugs for Neglected Diseases initiative 329
 - Medicines for Malaria Venture 329
 - as merited goods 350
 - orphan diseases 329
 - pricing *see* pharmaceutical pricing
 - privately-funded research 329
 - research/potential profit correlation 329–30
 - traditional medicine 328
- public interest
 - case law
 - Ashdown v Telegraph Group Limited* 23–5, 28
 - Attorney General v Guardian Newspapers (Spycatcher)* 19
 - Beggars Banquet v Carlton* 21–2, 27
 - Beloff v Pressdram Limited* 20, 28
 - British Leyland Motor Company Ltd v Armstrong Patent Co Ltd* 25–6, 27
 - broadening scope of 20
 - Canon Kabushiki Kaisha v Green Cartridge Co (Hong Kong) Ltd* 26
 - disclosure of information 19–20
 - Glynn v Weston Feature Film Co* 19
 - Hyde Park Residence v Yelland* 22–3, 24, 28
 - Lion Laboratories Ltd v Evans* 20–21, 27
 - Mars UK Ltd v Teknowledge Ltd* 26
 - Service Corporation International v Channel Four* 22, 27
 - confidentiality 15, 19–21, 23–4, 27, 228, 285
 - court readings of 18
 - defence 12
 - disclosure of copyright works 25

- and EU copyright law 28–9
- as fundamental principle of law 15
- historical UK court use of in public interest 18–19
- public security 19
- three-step test *see* three-step test
- remuneration 38
 - authors' rights model 40
 - additional compensation 40–41
 - right to equitable remuneration 41–2
 - term of protection 41
 - bargained-for payments 38
 - Das Boot* case 40–41
 - US model
 - digital audio transmission
 - exception 39–40
 - matter of contract in 38
 - Music Modernization Act (2018) 39–40
 - on-demand royalties 39, 40
 - statutory licensing scheme 39
 - voluntary licensing scheme 39
- resale rights
 - benefiting heirs of successful artists 85
 - and collecting societies 85–6
 - EU law 79–80
 - resale royalties *see* resale royalties
- resale royalties 78, 79–81
 - applicability 80
 - as discrimination-reducing tools 82–3
 - economic effects of 84
 - incentives to invest 86–7
 - market distortions 87–8
 - wealth transfer 84–6
 - as intrinsically fair 83–4
 - as poverty-mitigation tools 81–2
 - superstar effect 85
 - where not applicable 80–81
- revocation rights 44
 - authors' rights model
 - EU 44–5
 - France 44
 - Germany 44
 - recording artists 44–5
 - time limits 45
- US model
 - degree of predictability in 47
 - minimizing uncertainty 46
 - termination right 44, 45–6, 48
 - time limits on termination right 46–7
- right to education 96
 - access to textbooks 96, 97–9, 107–9
 - bulk copying problem 103–4
 - copyright inhibiting 98–9
 - as distant dream 100
 - extraterritorial state obligations 113–22
 - and IP law 99–100
 - for libraries 104–5
 - printed books 97–8
 - and TRIPS norms 100
 - in Art 13 ICESCR 107–8, 109
 - acceptability in 108–9
 - accessibility 108
 - accessible higher education 108
 - accessible secondary education 108
 - availability in 108
 - compulsory primary education 108
 - copyright limitations & exceptions
 - applicability 119–20
 - in Berne Convention 101–2, 105–7, 109
 - no single educational 104
 - not compulsory 103
 - personal use 101
 - proportionality test 102–3
 - public interest 101
 - quotations 101
 - reproduction 102, 105–6
 - teaching 101–2, 120
 - three-step test *see* three-step test
 - translations 104, 105, 120
 - draft Access to Knowledge Treaty (2005) 117
 - as hybrid right 107
 - in Maastricht Principle 14 113
 - in Maastricht Principle 15 111–12
 - in Maastricht Principle 17 112

- in Maastricht Principle 29 112–13
- see also* extraterritorial state
 - obligations; human rights;
 - ICESCR
- self-determination
 - and fairness 231
 - as normative fairness tool 218, 226
 - of Indigenous peoples 217, 218, 219, 221
 - operationalizing 234
 - knowledge commons 235–8
 - privacy by design 234–5
 - public sphere 240–41
- Stockholm Act (1967), UK accession to 13
- Switzerland-Uruguay BIT 183
- three-step test 13–14, 102–3, 114, 116, 126
 - certain special cases 26–8
 - compliance with 13
 - and human rights 119, 122
 - as guideline 16, 18
- trade secrets 5, 288–90
 - damages *see* trade secrets damages
 - employees as threat to 288–9
 - EU Trade Secrets Directive 290, 309
 - abusive litigation 299
 - balancing rights and interests 294
 - compensation 297
 - continued use against guarantee 296–7
 - employee mobility 291
 - harmonization 290, 293, 298
 - implementation 292
 - injunctions 294
 - judicial discretion 295–6
 - proportionality principle 291–2, 293
 - remedies 291
 - time limits 294–5
 - unfair competition approach 290
 - final injunctions 293, 298–300
 - fragility of 295
 - injunctions 293–5, 305
 - as preventive 305
 - legislative framework for 289–90
 - post-employment duties 309
 - preliminary injunctions 293, 295–8
 - springboard 297–8, 299
 - termination 298
 - protection of 289
 - see also* EU, Directive (EU) 2016/943
 - trade secrets damages 300–305
 - calculation 302
 - and balance of interests 304–5
 - non-economic factors in 303
 - reasonable royalty 304
 - in lieu of injunction 306–9
 - as akin to compulsory licence 307
 - application 306
 - compensation for loss 305
 - and ‘innocent’ third parties 308
 - with limitation 306
 - and proportionality 307
 - without limitation 307–8
 - limitation of liability 300, 301–2
 - safe harbour 56, 57, 351
 - minimum harmonization 300, 302–3
 - safeguards 300–301
- trademarks 141
 - for food products 208–9
 - Madrid Agreement 208
 - Madrid Protocol 208
 - non-traditional 208
 - product shapes 208–9
- traditional cultural expressions 216, 217, 224, 225, 229
 - access to Indigenous data 226–7, 228–9, 241–2
 - clash of knowledge systems 227
 - concerns over 227–8
 - creatives commons licences 236–7
 - culturally appropriate sharing 225
 - FirstVoices 233
 - fluid situation of 229
 - Indigenous data sovereignty *see* Indigenous data sovereignty
 - Indigenous digitization 232

- Indigenous labels and licences 233
 - Indigenous management of 233
 - Indigenous thesaurus projects 232
 - IsumaTV 233
 - Local Contexts project 233–4
 - mainstream libraries 232
 - Murkutu 233, 234
 - openness default 230
 - policy recognition of issue 228–9
 - protocols for handling Indigenous heritage 232–3
 - regulation 230
 - in UNDRIP 231
 - and copyright 222
 - analytical difficulties 224
 - lack of protection 230
 - cultural assimilation 221
 - cultural destruction 221
 - and fairness 229–30
 - legal approaches 230–31
 - participation 230, 231
 - self-determination 231
 - WIPO proposed *sui generis* regime 230
 - Indigenous data sovereignty *see*
 - Indigenous data sovereignty as more than commonalities 237–8
 - and power relations 224, 225
 - practical approaches 232–4
 - protections of 225
 - proposed minimum exceptions 230
 - see also* digital libraries; Indigenous peoples; traditional knowledge
 - traditional knowledge 5, 215, 234
 - Indigenous data sovereignty *see*
 - Indigenous data sovereignty *kaitiaki* 236
 - labels 234
 - Local Context Traditional Knowledge labels 236
 - licences 234
 - creative commons 236–7
 - TK/TCE common-pool resource
 - governance 236, 237
 - see also* digital libraries; Indigenous data sovereignty; Indigenous peoples; traditional cultural expressions
- TRIPS Agreement 2, 3
 - absolute protection of GIs 203
 - Art 1.3 211
 - Art 7 114, 118–19, 122
 - Art 8 114, 118–19, 122, 210
 - proposed Art 8a 116
 - Art 9(1) 13
 - Art 13 103, 116
 - Art 15.1 208
 - Art 17 209
 - Art 27 246
 - Art 27(1) 188–9
 - Art 27.2 1
 - Art 30 18
 - Art 39-3 1
 - copyright protection 98
 - extraterritorial state obligations and
 - right to education 116
 - minimum protection of GIs 203
 - non-traditional trademarks 208
 - not imposing uniform IP standards 190
 - ordre public in 210
 - sec 104A 50, 51
- UK
- business model reforms 168
 - Companies Act (2006) 147, 155
 - sec 172 154–5, 165, 167, 168
 - Copyright Act (1956), fair dealing in 13
 - Copyright and Related Rights Regulations (2003) 15
 - Copyright Designs and Patents Act (1988)
 - common law powers of 11, 12
 - history 10–11
 - and public interest 10–11
 - sec 171(3) 9, 11–12, 14–15
 - context 10
 - sec 30 13
 - statutory limitations and
 - exceptions in 11
 - uncertainty of Brexit impact on 14

- Copyright Designs and Patents Act (1998), fair dealing 126
- corporate governance *see* UK corporate governance
- Health Service Medical Supplies (Costs) Act (2017) 348
- historical court prevention of copyright 18
- Human Rights Act (1998) 24
- Intellectual Property Regulation Board 166
- Non-Financial Reporting Regulations 168
- UK corporate governance
- board effectiveness reviews 157–61, 171
 - FRC Guidance 156, 157–8
 - questions for boards 158–60
 - business judgment rule 160–61, 163
 - as shield from accountability 163–4
 - Corporate Governance Code (2018) 154, 165
 - directors' accountability 154
 - directors' duties 154–5
 - due diligence 163
 - duty of care 160
 - good faith 155
 - honesty 163
 - express reference to IP and technology 155–6
 - Financial Reporting Council
 - Corporate Culture and Role of Boards recommendations 155
 - initiatives 156–7
 - Guidance on Board Effectiveness (2018) 165, 168, 169
 - standard of care 163
 - Stewardship Code 154, 171
 - see also* IP, and corporate governance
- UN
- 2030 Agenda 225
 - CESCR
 - General Comment No. 3 109
 - interpretation of Art 13 ICESCR 108
 - Charter 109
 - Declaration on the rights of Indigenous Peoples (2007) *see* UNDRIP
 - Report of the High Level Panel on access to medicines (2016) 329–30, 331
 - Sustainable Development Goals 225
 - see also* ICESCR; Indigenous peoples; right to education
 - UNDRIP 217
 - Art 3 239
 - Art 13 231
 - Art 31 231, 239
 - UNESCO Convention on the protection and promotion of the Diversity of Cultural Expressions (2005) 237
 - unfair competition 44
 - Anti-unfair Competition Law (China) *see* Anti-unfair Competition Law in EU Trade Secrets Directive 290
 - EU/US comparison 32
 - and morality 1
 - protection from free-riding 209
 - US/EU differentiation 32
 - Uruguay
 - tobacco products
 - 80/80 regulation 185
 - SPR requirement 185–6
 - see also* investment arbitration
 - US
 - Computer and Communications Industry Association 58
 - Copyright Act (1976) 125–6
 - sec 107 13, 60
 - sec 110(5)(b) 16
 - Drug Price Competition and Patent Term Restoration Act (1984) 343
 - few moral rights 31
 - Health Care and Education and the Health Care and Education Reconciliation Act 337–8
 - law favoring capital over labour 31
 - Music Modernization Act (2018) 39–40

- quasi-copyright protection for older recordings 40
- Patient Protection and Affordable Care Act 337, 338
- Sherman Antitrust Act (1890) 334
- Sound Recording Act (1971) 40
- Visual Artists Rights Act 43
- US–Mexico–Canada Agreement 179
 - Art 14.6(1) 179
 - Art 14.6(2) 179–80
 - Art 14.6(3) 190
- value gap 2
- WHO
 - Expert Advisory Panel on the International Pharmacopoeia
 - and Pharmaceutical Preparations 335
 - INN system 335
- WIPO
 - Development Agenda 118
 - Draft Articles (2018)
 - Art 7(1) 230
 - minimum exception to TCE protection 230
 - /human rights contrast 217
 - need to be informed by fairness point of view 225
 - Performances and Phonograms Treaty 43